As an investment holding enterprise, Viva Biotech Holdings provides comprehensive drug discovery services, leveraging a structure-based approach for biotechnology and pharmaceutical clients across the globe. Their offerings encompass discovery biology, including protein expression and purification, structural biology, identification of promising drug candidates (hit discovery), bioassay development, analysis of biomolecular interactions, and pharmacokinetics. They also deliver a range of chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, preparation for purification, and computer-aided drug design (CADD), supported by advanced chemical technology platforms. Furthermore, Viva Biotech excels in antibody drug research and development. These services span from antigen preparation and multi-species discovery to the generation of monoclonal antibodies, functional screening and identification, engineering transformation, characterization, and cell line engineering. They utilize a suite of sophisticated technology platforms for this, including hybridoma, phage, yeast, and mammalian display systems, VHH antibody technology, high-throughput sequencing, computer-aided drug design (CADD), HDX-MS, protein crystal structure determination, and SPR technology. The company additionally supplies crucial research materials such as cell lines, crystal structures, GPCR proteins, various antibodies, and other key proteins. Beyond R&D, Viva Biotech offers contract development and manufacturing (CDMO) for small molecule active pharmaceutical ingredients (APIs) and their intermediates. They are also involved in the trading of APIs, intermediates, and finished formulations, and uniquely provide an "equity for service" model. Additional services include general research support, laboratory space rental, project management, bidding assistance, and the sale of chemical compounds. Established in 2008, the company is headquartered in Shanghai, China.